Rockefeller University scientists have analysed soils from beaches, forests, and deserts on five continents and discovered the best places in the world to mine untapped antibiotic and anticancer drugs.
The findings, published in the open-access journal eLife, provide new insights into the natural world as well as a road map for future drug discovery. The scientists now want to collect more samples from unique environments such as caves, hot springs, islands and city parks. They will continue with their citizen science effort, Drugs from Dirt, inviting the public to submit samples.
While there are more microbes in a teaspoon of soil than there are humans on earth, only a tiny fraction have been cultured. Of these, only a small number of the potentially clinically useful chemicals produced by bacteria have been studied.
For this study, one hundred and eighty five samples were taken from rainforests, temperate forests, deserts, and beaches on five continents (North America, South America, Africa, Asia and Australia) and the oceanic islands of Hawaii and Dominican Republic. The study of the “biosynthetic” content of these soils shows their potential for drug discovery.
“Uncultured bacteria from the environment could provide a dazzling array of new molecules, many of which could become new medicines,” says lead author and postdoctoral fellow Zachary Charlop-Powers from The Rockefeller University in New York.
“The unbelievable diversity we found is a first step towards our dream of building a world map of chemicals produced by microbes — similar to Google Earth’s and others’ maps of the world’s geography,” says Dr Sean Brady, head of the Laboratory of Genetically Encoded Small Molecules also at The Rockefeller University in New York.
The vast majority of antibiotics in clinical use today are derived from soil bacteria, but the yield of new drugs is low because the same cultivated bacteria, and the set of molecules they synthesise, are repeatedly rediscovered. However, for every cultured bacterial species, there are 100 uncultivated species in the environment.
Scientists have previously identified clusters of bacterial genes that are particularly good at producing therapeutics. This knowledge meant the scientists could focus on searching for certain types of gene clusters in samples rather than having to sequence and analyse the whole genomes of bacteria.
The team compared environmentally derived DNA to DNA from laboratory-grown bacteria chosen for their ability to make more than 400 natural product compounds. The analysis revealed soils particularly rich in important gene clusters.
The Latest on: Drug discovery
via Google News
The Latest on: Drug discovery
- CULTIVATED: Cyclica raises $17 million for drug discovery — Aurora Cannabis lays off workers — Barr holds up cannabis mergerson June 26, 2020 at 8:02 am
In this edition, we bring you AI drug discovery startup Cyclica's Series B deck, break down cuts at Aurora, and more.
- Drug Discovery Technologies Market Size will Grow Profitably in the Near Future 2020-2026on June 26, 2020 at 5:46 am
Increasing binge eating and consumption of junk foods, neglect towards regular exercise, rising levels of stress, are key market drivers. The report discusses more information about these subjects, ...
- North American Artificial Intelligence (AI) in Drug Discovery Market 2020-2026 - ResearchAndMarkets.comon June 26, 2020 at 4:28 am
The "North America Artificial Intelligence (AI) in Drug Discovery Market 2020-2026 by Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Country: Trend Forecast and Growth ...
- Artificial Intelligence in Drug Discovery Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027on June 25, 2020 at 11:34 am
The Global Artificial Intelligence in Drug Discovery Market is anticipated to value over USD 2.08 billion by 2027 end with a CAGR of over 40.5% during the forecast period 2020 to 2027. The rising ...
- High-Performance Cloud Speeds Drug Discovery And Moreon June 25, 2020 at 2:08 am
GridMarkets runs its rendering platform on Oracle Cloud Infrastructure, speeding production of ultraheavy workloads at scale.
- Sosei, AbbVie sign drug discovery deal worth up to $1 blnon June 25, 2020 at 1:03 am
Japan's Sosei Group Corp will collaborate with AbbVie Inc on a drug discovery partnership that could be worth up to $1 billion. Sosei shares soared 12.4% in Tokyo trading, compared with a 1.2% slide ...
- Sosei, AbbVie sign drug discovery deal worth up to $1 billionon June 25, 2020 at 12:44 am
Chicago-based AbbVie has the option to expand the collaboration to a total of four targets. An expansion to four targets would put the total deal size "in a similar ballpark" to deals signed in 2019 ...
- Japan's Sosei Group signs $377 mln drug discovery deal with Abbvieon June 24, 2020 at 7:44 pm
Japan's Sosei Group Corp 4565.T will collaborate with Abbvie Inc ABBV.N on drug discovery in a deal worth up to $377 million, the companies said on Thursday. S ...
- Cyclica raises $23 million to accelerate drug discovery with AIon June 23, 2020 at 10:00 pm
Cyclica, a startup developing an AI-powered platform for drug discovery, has secured $23 million in venture capital financing.
- BRIEF-Schrödinger Collaborates With Thermo Fisher To Expand Structure-Based Drug Discoveryon June 23, 2020 at 4:27 am
SCHRÖDINGER ANNOUNCES STRATEGIC COLLABORATION WITH THERMO FISHER SCIENTIFIC TO EXPAND STRUCTURE-BASED DRUG DISCOVERY TO NOVEL TARGETS USING CRYO-EM * SCHRODINGER - STRATEGIC COLLABORATION WITH THERMO ...
via Bing News